Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma

Seminars in Liver Disease

Volumn 30, Issue 1, 2010, Pages 75-86

  Imbeaud, Sandrine ^a,b   Ladeiro, Yannick ^a,b   Zucman Rossi, Jessica ^a,b,c  

^a Université Paris 13   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Benign tumor; Beta catenin; Gene mutation; Genomic; Gp130; Hepatocellular adenoma; Hepatocellular carcinoma; Malignant transformation; MiRNA; Oncogene; Stat3; TP53; Transcriptome; Tumor suppressor gene

Indexed keywords

BETA CATENIN; CATENIN; GLYCOPROTEIN GP 130; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; MICRORNA; TRANSCRIPTOME; WNT PROTEIN;

CARCINOGENESIS; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW; TP53 GENE; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE;

CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; LIVER NEOPLASMS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ONCOGENES; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEINS;

EID: 77349085585     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0030-1247134     Document Type: Review

References (120)

1. Parkin D M. Global cancer statistics in the year 2000. Lancet Oncol 2001 2 (9) 533-543
2. El-Serag H B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004 127 (5, Suppl 1) S27-S34
3. McGlynn K A., London W T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005 19 (1) 3-23
4. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005 25 (2) 143-154
5. Taylor-Robinson S D., Foster G R., Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997 350 (9085) 1142-1143
6. Donato F, Gelatti U, Limina R M., Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 2006 25 (27) 3756-3770
7. Seeff L B., Hoofnagle J H. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006 25 (27) 3771-3777
8. Bralet M P., Régimbeau J M., Pineau P et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000 32 (2) 200-204
9. Lee J S., Chu I S., Heo J et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004 40 (3) 667-676
10. Lee J S., Heo J, Libbrecht L et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006 12 (4) 410-416
11. Villanueva A, Newell P, Chiang D Y., Friedman S L., Llovet J M. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007 27 (1) 55-76
12. Boyault S, Rickman D S., de Reynis A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007 45 (1) 42-52
13. Cieply B, Zeng G, Proverbs-Singh T, Geller D A., Monga S P. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009 49 (3) 821-831
14. de La Coste A, Romagnolo B, Billuart P et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998 95 (15) 8847-8851
15. Huang H, Fujii H, Sankila A et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999 155 (6) 1795-1801
16. Legoix P, Bluteau O, Bayer J et al. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999 18 (27) 4044-4046
17. Miyoshi Y, Iwao K, Nagasawa Y et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998 58 (12) 2524-2527
18. Taniguchi K, Roberts L R., Aderca I N. et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002 21 (31) 4863-4871
19. Terris B, Pineau P, Bregeaud L et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999 18 (47) 6583-6588
20. Wong C M., Fan S T., Ng I O. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001 92 (1) 136-145
21. Ishizaki Y, Ikeda S, Fujimori M et al. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol 2004 24 (5) 1077-1083
22. Kim Y D., Park C H., Kim H S. et al. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J Gastroenterol Hepatol 2008 23 (1) 110-118
23. Laurent-Puig P, Legoix P, Bluteau O et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001 120 (7) 1763-1773
24. Park J Y., Park W S., Nam S W. et al. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005 25 (1) 70-76
25. Satoh S, Daigo Y, Furukawa Y et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000 24 (3) 245-250
26. Zucman-Rossi J, Benhamouche S, Godard C et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007 26 (5) 774-780
27. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. [see comments] Nature 1991 350 (6317) 429-431
28. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 1995 22 (6) 1702-1707
29. Honda K, Sbis E, Tullo A et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998 77 (5) 776-782
30. Hussain S P., Schwank J, Staib F, Wang X W., Harris C C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007 26 (15) 2166-2176
31. Challen C, Guo K, Collier J D., Cavanagh D, Bassendine M F. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 1992 14 (2-3) 342-346
32. Leon M, Kew M C. Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res 1995 15 (3) 859-861
33. Takada S, Koike K. Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells. Oncogene 1989 4 (2) 189-193
34. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989 80 (3) 196-199
35. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 2001 84 (7) 982-989 (Pubitemid 32385844)
36. Bluteau O, Jeannot E, Bioulac-Sage P et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002 32 (2) 312-315
37. Rebouissou S, Amessou M, Couchy G et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009 457 (7226) 200-204
38. Zhang X, Xu H J., Murakami Y et al. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994 54 (15) 4177-4182
39. Chen T C., Hsieh L L., Kuo T T. et al. p16INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma. Anticancer Res 2000 20 (3A, 3A) 1621-1626
40. Kita R, Nishida N, Fukuda Y et al. Infrequent alterations of the p16INK4A gene in liver cancer. Int J Cancer 1996 67 (2) 176-180
41. Liew C T., Li H M., Lo K W. et al. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999 18 (3) 789-795
42. Lee J W., Soung Y H., Kim S Y. et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005 24 (8) 1477-1480
43. Tanaka Y, Kanai F, Tada M et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2006 25 (20) 2950-2952
44. Kawate S, Takenoshita S, Ohwada S et al. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol 1999 14 (1) 127-131
45. Yakicier M C., Irmak M B., Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999 18 (34) 4879-4883
46. Bae J J., Rho J W., Lee T J. et al. Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol Rep 2007 18 (4) 1007-1013
47. Fujiwara Y, Hoon D S., Yamada T et al. PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res 2000 91 (3) 287-292
48. Kawamura N, Nagai H, Bando K et al. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res 1999 90 (4) 413-418
49. Wang Y, Lee A T., Ma J Z. et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008 283 (19) 13205-13215
50. Yao Y J., Ping X L., Zhang H et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999 18 (20) 3181-3185
51. De Souza A T., Hankins G R., Washington M K., Orton T C., Jirtle R L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995 11 (4) 447-449
52. Oka Y, Waterland R A., Killian J K. et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002 35 (5) 1153-1163
53. Yamada T, De Souza A T., Finkelstein S, Jirtle R L. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci U S A 1997 94 (19) 10351-10355
54. Park W S., Dong S M., Kim S Y. et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999 59 (2) 307-310
55. Yang D H., Huang W, Cui J et al. The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004 3 (1) 86-89
56. Kim C J., Cho Y G., Park J Y. et al. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur J Cancer 2004 40 (1) 136-141
57. Pelletier L, Rebouissou S, Paris A et al. Loss of HNF1a function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology 2009 51 (2) 557-566
58. Zucman-Rossi J, Jeannot E, Nhieu J T. et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006 43 (3) 515-524
59. Bioulac-Sage P, Rebouissou S, Thomas C et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007 46 (3) 740-748
60. Chen Y W., Jeng Y M., Yeh S H., Chen P J. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002 36 (4 Pt 1) 927-935
61. Van der Borght S, Libbrecht L, Katoonizadeh A et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 2007 51 (6) 855-856
62. Cavard C, Colnot S, Audard V et al. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol 2008 4 (5) 647-660
63. Nagafuchi A, Takeichi M. Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1989 1 (1) 37-44
64. Micsenyi A, Tan X, Sneddon T, Luo J H., Michalopoulos G K., Monga S P. Beta-catenin is temporally regulated during normal liver development. Gastroenterology 2004 126 (4) 1134-1146
65. Suksaweang S, Lin C M., Jiang T X., Hughes M W., Widelitz R B., Chuong C M. Morphogenesis of chicken liver: identification of localized growth zones and the role of beta-catenin/Wnt in size regulation. Dev Biol 2004 266 (1) 109-122
66. Monga S P., Monga H K., Tan X, Mulé K, Pediaditakis P, Michalopoulos G K. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003 124 (1) 202-216
67. Benhamouche S, Decaens T, Godard C et al. Apc tumor suppressor gene is the zonation-keeper of mouse liver. Dev Cell 2006 10 (6) 759-770
68. Cadoret A, Ovejero C, Terris B et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002 21 (54) 8293-8301
69. Monga S P., Pediaditakis P, Mule K, Stolz D B., Michalopoulos G K. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 2001 33 (5) 1098-1109
70. Tan X, Behari J, Cieply B, Michalopoulos G K., Monga S P. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 2006 131 (5) 1561-1572
71. Audard V, Grimber G, Elie C et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 2007 212 (3) 345-352
72. Fujito T, Sasaki Y, Iwao K et al. Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma. Hepatogastroenterology 2004 51 (58) 921-924
73. Hsu H C., Jeng Y M., Mao T L., Chu J S., Lai P L., Peng S Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000 157 (3) 763-770
74. Chiang D Y., Villanueva A, Hoshida Y et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008 68 (16) 6779-6788
75. Ovejero C, Cavard C, Périanin A et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 2004 40 (1) 167-176
76. Lieu H T., Batteux F, Simon M T. et al. HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice. Hepatology 2005 42 (3) 618-626
77. Renard C A., Labalette C, Armengol C et al. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res 2007 67 (3) 901-910
78. Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009 136 (3) 1012-1024
79. Baum J K., Bookstein J J., Holtz F, Klein E W. Possible association between benign hepatomas and oral contraceptives. Lancet 1973 2 (7835) 926-929
80. Christopherson W M., Mays E T., Barrows G. A clinicopathologic study of steroid-related liver tumors. Am J Surg Pathol 1977 1 (1) 31-41
81. Edmondson H A., Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976 294 (9) 470-472
82. Lansing P B., McQuitty J T., Bradburn D M. Benign liver tumors: what is their relationship to oral contraceptives? Am Surg 1976 42 (10) 744-760
83. Rooks J B., Ory H W., Ishak K G. et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979 242 (7) 644-648
84. Vana J, Murphy G P., Aronoff B L., Baker H W. Primary liver tumors and oral contraceptives. Results of a survey. JAMA 1977 238 (20) 2154-2158
85. Kent D R., Nissen E D., Nissen S E., Ziehm D J. Effect of pregnancy on liver tumor associated with oral contraceptives. Obstet Gynecol 1978 51 (2) 148-151
86. Kerlin P, Davis G L., McGill D B., Weiland L H., Adson M A., Sheedy P F. II. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983 84 (5 Pt 1) 994-1002
87. Foster J H., Berman M M. The malignant transformation of liver cell adenomas. Arch Surg 1994 129 (7) 712-717
88. Grigsby P, Meyer J S., Sicard G A., Huggins M B., Lamar D J., DeSchryver-Kecskemeti K. Hepatic adenoma within a spindle cell carcinoma in a woman with a long history of oral contraceptives. J Surg Oncol 1987 35 (3) 173-179
89. Gyorffy E J., Bredfeldt J E., Black W C. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med 1989 110 (6) 489-490
90. Korula J, Yellin A, Kanel G, Campofiori G, Nichols P. Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. West J Med 1991 155 (4) 416-418
91. Tao L C. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer 1991 68 (2) 341-347
92. Bioulac-Sage P, Laumonier H, Couchy G et al. Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience. Hepatology 2009 50 481-489
93. Hsu I C., Metcalf R A., Sun T, Welsh J A., Wang N J., Harris C C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991 350 (6317) 427-428
94. Sun C A., Wang L Y., Chen C J. et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001 22 (8) 1289-1294
95. Bluteau O, Beaudoin J-C, Pasturaud P et al. Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 2002 21 (8) 1225-1232
96. Hoshida Y, Nijman S M., Kobayashi M et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009 69 (18) 7385-7392
97. Chen X, Cheung S T., So S et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002 13 (6) 1929-1939
98. Breuhahn K, Vreden S, Haddad R et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 2004 64 (17) 6058-6064
99. Kaposi-Novak P, Lee J S., Gmez-Quiroz L, Coulouarn C, Factor V M., Thorgeirsson S S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006 116 (6) 1582-1595
100. Coulouarn C, Factor V M., Thorgeirsson S S. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008 47 (6) 2059-2067
101. Yamashita T, Forgues M, Wang W et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008 68 (5) 1451-1461
102. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008 359 (19) 1995-2004
103. Cullen B R. Transcription and processing of human microRNA precursors. Mol Cell 2004 16 (6) 861-865
104. Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006 25 (17) 2537-2545
105. Kutay H, Bai S, Datta J et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006 99 (3) 671-678
106. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob S T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007 133 (2) 647-658
107. Gramantieri L, Ferracin M, Fornari F et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007 67 (13) 6092-6099
108. Huang Y S., Dai Y, Yu X F. et al. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol 2008 23 (1) 87-94
109. Jiang J, Gusev Y, Aderca I et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008 14 (2) 419-427
110. Varnholt H, Drebber U, Schulze F et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008 47 (4) 1223-1232
111. Ladeiro Y, Couchy G, Balabaud C et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008 47 (6) 1955-1963
112. Connolly E, Melegari M, Landgraf P et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008 173 (3) 856-864
113. Budhu A, Jia H L., Forgues M et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008 47 (3) 897-907
114. Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009 361 (15) 1437-1447
115. Ji J, Yamashita T, Budhu A et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009 50 (2) 472-480
116. Ura S, Honda M, Yamashita T et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009 49 (4) 1098-1112
117. Huang X H., Wang Q, Chen J S. et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009 39 (8) 786-794
118. Su H, Yang J R., Xu T et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009 69 (3) 1135-1142
119. Li S, Fu H, Wang Y et al. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2009 49 (4) 1194-1202
120. Coulouarn C, Factor V M., Andersen J B., Durkin M E., Thorgeirsson S S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009 28 (40) 3526-3536